Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Stojdl

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Molecular Cell|April 2, 2003
An integrated stress response regulates amino acid metabolism and resistance to oxidative stressHeather P Harding, Yuhong Zhang, Huiquing Zeng, et al.
Cancer Cell|October 31, 2003
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F Stojdl, Brian D Lichty, Benjamin R tenOever, et al.
Cancer Cell|October 22, 2011
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell deathDouglas J Mahoney, Charles Lefebvre, Kristina Allan, et al.
Oncolytic Virotherapy|December 13, 2018
Development and applications of oncolytic Maraba virus vaccinesJonathan G Pol, Matthew J Atherton, Byram W Bridle, et al.
Cancer Immunology Research|September 16, 2017
Customized Viral Immunotherapy for HPV-Associated CancerMatthew J Atherton, Kyle B Stephenson, Jonathan Pol, et al.
Cancer Immunology Research|February 5, 2017
NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular VaccineAlmohanad A Alkayyal, Lee-Hwa Tai, Michael A Kennedy, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, Hesham Abdelbary, Meztli Arguello, et al.
Molecular Therapy Oncolytics|December 3, 2016
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodiesLaura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, et al.
Oncoimmunology|June 15, 2018
Transforming the prostatic tumor microenvironment with oncolytic virotherapyMatthew J Atherton, Kyle B Stephenson, Fanny Tzelepis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2014
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseJiqing Zhang, Lee-Hwa Tai, Carolina S Ilkow, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Molecular Cell|April 2, 2003
An integrated stress response regulates amino acid metabolism and resistance to oxidative stressHeather P Harding, Yuhong Zhang, Huiquing Zeng, et al.
Cancer Cell|October 31, 2003
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agentsDavid F Stojdl, Brian D Lichty, Benjamin R tenOever, et al.
Cancer Cell|October 22, 2011
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell deathDouglas J Mahoney, Charles Lefebvre, Kristina Allan, et al.
Oncolytic Virotherapy|December 13, 2018
Development and applications of oncolytic Maraba virus vaccinesJonathan G Pol, Matthew J Atherton, Byram W Bridle, et al.
Cancer Immunology Research|September 16, 2017
Customized Viral Immunotherapy for HPV-Associated CancerMatthew J Atherton, Kyle B Stephenson, Jonathan Pol, et al.
Cancer Immunology Research|February 5, 2017
NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular VaccineAlmohanad A Alkayyal, Lee-Hwa Tai, Michael A Kennedy, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, Hesham Abdelbary, Meztli Arguello, et al.
Molecular Therapy Oncolytics|December 3, 2016
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodiesLaura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, et al.
Oncoimmunology|June 15, 2018
Transforming the prostatic tumor microenvironment with oncolytic virotherapyMatthew J Atherton, Kyle B Stephenson, Fanny Tzelepis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2014
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseJiqing Zhang, Lee-Hwa Tai, Carolina S Ilkow, et al.
Pageof 4